Abstract: In accordance with the present invention, a cDNA clone encoding a new human .beta. subunit which was designated .beta..sub.5 was found. Probes for this nucleotide sequence are described. In addition, the .beta..sub.5 protein, its associated subunit and its cell distribution were characterized. In another embodiment, this invention relates to assays for detecting this protein. .beta..sub.5 subunit was found present on carcinomas, but absent from lymphoid cells. Consequently, this protein can be used to determine the presence of carcinoma.

Abstract: The present invention relates to a method for determining a lipophilic compound, comprising using an antibody tolerant to one or more organic solvents, and carrying out an antigen-antibody reaction in the presence of one or more organic solvents. By the present method, it is possible to perform an antigen-antibody reaction of the lipophilic compound and the antibody, using an extract of a sample by one or more organic solvents, and thus the procedure becomes simple.Further, the present invention also relates to a monoclonal antibody specific to at least okadaic acid, dinophysistoxin-1 and dinophysistoxin-3, a hybridoma which produces the above monoclonal antibody, and an immunological determination method of diarrheal shellfish poisons using the above monoclonal antibody. According to the present invention, specific determination of all the three types of diarrheal shellfish poisons becomes possible.

Abstract: Antibodies raised against derivatives of inositol are used to assay for specific isomers of inositol in a sample by first converting any inositol present in the sample to the derivative that was used to raise the antibody and then conducting an immunoassay for the inositol derivative in a conventional manner.

Abstract: A new homogeneous cytosolic binding protein (FKBP-14.6 immunophilin) having a molecular weight of about 14.6 kDa (calculated from its amino acid composition), reversibly binds the immunosuppressive drugs FK-506, rapamycin or chemically related compounds, but not cyclosporine. The FKBP-14.6 protein has a pI of 6.5-7.5, and the (partial) N-terminal amino acid sequence: NH.sub.2 -Lys-Leu-Pro-Tyr-Glu-Leu-Lys-X-Asn-Val-Lys-Ala-Phe-X-X-Lys-Val- (where X is undefined), and partial internal amino acid sequences -Val-Leu-Asp-Thr-Ala-Tyr-Glu-Tyr-Gly-Ala-Glu-Ala-Leu-Glu-, -Glu-Phe-Thr-Pro-Val-Phe-Gln-Ala-X-Phe- and -Ser-Leu-Val-Pro-Leu-Val-Gly-X-Lys- (where X is undefined). This N-terminal amino acid sequence exhibits no homology to FKBP-12 or membrane-associated FKBP-13. THe FKBP-14.6 is isolated from the cytosol of mammalian tissues, preferably calf thymus, and can be used in diagnostic and purification procedures involving FK-506 and rapamycin-type immunosuppressant drugs.

Abstract: Novel derivatives of procainamide and N-acetylprocainamide (NAPA) are disclosed having the following formula: ##STR1## wherein: X=hydrogen or acetyl;n=1 to p where p=MW of Z/1000;Z=a poly(amino acid) or polysaccharide; andR3=a bond or ##STR2## wherein R2=an alkyl, cycloalkyl or aryl group having 2 to 10 carbon atoms. The derivatives include maleimide conjugates of proteins or poly(amino acids), enzymes, enzyme donor polypeptides and labeling substances. Novel activated hapten intermediates useful in the preparation of the conjugates and methods for synthesis of the hapten intermediates and derivatives are also disclosed.

Abstract: An antibody test suitable for the rapid detection of ciguatoxin and other related low molecular weight polyether marine lipid toxins in fish tissue in the field or laboratory is disclosed. The test utilizes the reaction between antibody coated, mixed latex beads and any lipids in an extract of a sample of fish tissue eluted in a solvent. The presence of toxins is determined within about thirty minutes by ascending chromatography, which separates the mixed beads. The toxin concentration is determined by reference to standard data. A kit suitable for performing the testing procedure in the field is also disclosed. The kit includes a support having a nylon membrane covering, and antibody coated, mixed beads applied on the membrane, a testing container, a supply of solvent and a biopsy tool.

Abstract: This invention provides a method of altering the metabolism of sphingolipids in a cell comprising contacting the cell with a fumonisin, or an analog thereof. The invention also provides a method of detecting the consumption of a fumonisin or a fumonisin analog in a subject comprising (A) detecting, in a sample from the subject, the state of the metabolic pathway of sphingolipids and (B) comparing the state of the metabolic pathway to that of a normal subject, the presence of a change in the state of the metabolic pathway indicating the consumption of a fumonisin or a fumonisin analog. Also provided is a method of detecting the presence of a fumonisin or fumonisin analog contamination in a sample from a food or feed comprising detecting a reaction of the metabolic pathway of sphingolipids, the presence of the reaction indicating the presence of a fumonisin or fumonisin analog contamination. Furthermore, novel fumonisin analogs and compositions comprising fumonisins and fumonisin analogs are provided.

Abstract: As a carrier for binding of the antiphospholipid antibodies used for immunological diagnosis of antiphospholipid syndrome, a phospholipid-bound carrier treated with purified serum albumin and a surfactant is used. Thus, immunological diagnosis of antiphospholipid syndrome can be made with high accuracy. By using the fraction or protein obtained from animal serum or plasma, having the activity of enhancing the binding ability of the antibodies specifically present in the antiphospholipid syndrome to the phospholipid, immunological diagnosis of antiphospholipid syndrome can also be made more accurately, as compared to known diagnosis.

Abstract: A non-specific reaction suppressor for immunoassays having the formula: ##STR1## where R.sub.1, R.sub.2, Y, X, and R.sub.3 are defined in the specification.

Abstract: A method of assessin glycated blood protein in a sample which comprises separating glycated and non-glycated protein using a liquid phase precipitation reagent, contacting the sample before or during the separation with a signal forming agent capable of binding preferentially to the glycated protein, and assessing the signal forming agents.

Abstract: An immunoassay method for the detection or quantitation of an analyte suspected of being in a solution comprising: (a) combining said specimen, a first binding component, insoluble particles, and second binding component labelled with a signal generating material in a solid phase retention and separation apparatus having a sufficient pore size such that said particles are trapped within said filter yet permitting rapid passage of fluid therethrough in such a manner that an immunological reaction occurs if analyte is present in said specimen, resulting in the formation of an immunocomplex of insolublized first binding component:analyte:second labelled binding component on or within said filter means; (b) separating bound from unbound material; and (c) determining the presence and/or amount of signal produced which is correlative with the amount of analyte present in the solution.

Abstract: An assay device for detecting the presence of analytes in an unknown sample including a reaction system wherein storage reservoirs containing reagent are fluidly connected to a track containing the sample. An actuation mechanism forces the reagent from the reservoirs and into the track where it mixes the reagents together and then with the sample at a first flow rate. The mechanism then reduces the force on the reagent to allow a second flow rate less then the first flow rate to force the reagent and sample mixture through the track so that reaction can occur, whereby a determination as to whether the target analyte was present may be made.

Abstract: Cellular DNA repair enzyme activity has been found to be an indicator of susceptibility or predisposition of an individual to DNA associated diseases. The activity of the enzyme adenosine diphosphate ribosyl transferase (ADPRT) has been found to be a good indicator as to the susceptibility of an individual to DNA associated diseases, such as cancer.

Abstract: This invention pertains to methods to detect a compound in the presence of a homolog that is immunologically related to the analyte. The invention is particularly suited for the detection of homocysteine in the presence of cysteine. The methods of this invention involve chemically modifying both the analyte and the homolog to increase their immunogenicity and facilitate antibody recognition. More importantly, this modification is done to make these compounds immunologically distinct. Antibodies to the immunologically distinct compounds are then prepared. An assay protocol comprises chemically modifying the analyte and homolog and then immunochemically detecting the modified analyte by means of the aforementioned antibodies.

Abstract: A one reaction step method for determining hydrophobic analytes, such as free hydrophobic analytes, comprising the steps of mixing a solution suspected of containing the hydrophobic analyte, e.g. free fatty acid, with a reagent comprising a fluorescently modified specific-binding protein for the hydrophobic analyte, detecting a fluorescence difference between the fluorescently modified specific-binding protein in the bound and unbound condition, and relating said fluorescence difference to the amount of arialyre in the solution is disclosed.

Abstract: A method for the direct analysis of analyte indicative of marijuana exposure found in keratinized structures, e.g., hair, fingernails and toenails, which comprises preparing a mixture containing dithiothreitol or dithioerythritol, a protease suitable for the digestion of the keratin structure and a sample of the keratin structure; permitting the enzyme to at least substantially digest the sample of keratin structure to form a digest solution, followed by mixing the digest solution with a suspension of an ion exchange resin to remove an interfering, cross reacting substance naturally found in hair and finally subjecting the digest solution to analysis to determine the identity and amount of marijuana analyte in the keratin structure sample. To accelerate the method, cupric sulfate may be added to the mixture after degradation of the keratin sample in order to deactivate the activator. The enzyme may be a protease with papain, chymopapain, and proteinase K being preferred for use in the invention.

Abstract: Methods have been developed to produce novel compounds by covalently coupling thiazolidinedione insulin sensitivity enhancers (ISEs) to proteins. These novel compounds are well suited for producing antibodies, which are specific for thiazolidinedione ISEs and which are well suited for fluorescent immunoassays of thiazolidinedione and non-thiazolidinedione ISEs in buffers and biological tissues. Antibodies also are well suited for high-volume screening for immunologically related novel, non-thiazolidinedione and thiazolidinedione ISEs.

Abstract: Immunoassay techniques for quantitating the amount of 3'-amido-3'-deoxythymidine (AMT) in body fluid samples, and antibodies useful in performing such immunoassays, are provided. The immunoassays use antibodies which are specific to AMT and have no cross-reactivity with 3'-azido-3'-deoxythymidine (AZT). Moreover, there is provided an improved method of conducting AZT therapy wherein the concentration of both AZT and AMT is monitored and the AZT dosage is adjusted to maintain rather low concentrations of AMT.

Abstract: A method is provided for measuring the net HDL cholesterol in the blood. The LDL and VLDL moieties are precipitated out and the remaining cholesterol content of the supernatant is measured. The free cholesterol content of the supernatant is separately measured and substracted from the total to obtain net HDL cholesterol. This value serves as a useful indicator for diagnosing vascular disease. A diet supplement and method for raising serum HDL is provided.

Abstract: For the determination of vitamin B12 a sample solution is incubated with at least two receptors R.sub.1 and R.sub.2 of which R.sub.1 mediates the binding to the solid phase and R.sub.2 is labelled, whereby a receptor is used as one of the receptors R.sub.1 or R.sub.2 which contains a monoclonal antibody capable of specific binding to B12 that has an affinity constant of at least 5.times.10.sup.9 l/mol and a receptor is used as the other receptor R.sub.1 or R.sub.2 which contains B12 or an analogue thereof, the two phases are separated and the label is measured in one of the two phases.

Abstract: An immunoassay method that integrates a sample processing component that enables the testing of a variety of environmental matrixes and the components for performing the method, wherein the immunoassay utilizes a monoclonal anti-PAH antibody to detect the presence or absence of PAH contamination in a sample when tested in a field or laboratory location.

Abstract: Galactopyranoside derivative compounds for use as substrates for hydrolysis by enzymes with .beta.-galactosidase activity are provided. The concentration of the reaction products can be measured by spectroscopy. The compounds find particular use in diagnostic assays for detection of analyte.

Abstract: The invention relates to an agent and process for treating body fluids in the immunological determination of neopterin using a specific antibody against neopterin and a detection system. The agent is characterized in that it contains an oxidizing agent.

Abstract: A process for the detection of antibiotics in a liquid medium such as milk, urine and blood is disclosed which comprisesbringing together a fluid sample of the liquid medium, an labelled antibiotic binding protein, and an immobilized antibiotic,allowing the labelled antibiotic binding protein to bind with the immobilized antibiotic,removing labelled antibiotic binding protein which is not bound to immobilized antibiotic, anddetermining the amount of the labelled antibiotic binding protein bound to the immobilized antibiotic.

Abstract: A method is described for the use of monoclonal antibodies in a sensitive immunoassay for halogenated dioxins and dibenzofurans in industrial samples which contain impurities. Appropriate sample preparation and selective enzyme amplification of the immunoassay sensitivity permits detection of dioxin contaminants in industrial or environmental samples at concentrations in the range of a few parts per trillion.

Abstract: An enhanced quantitative assay for chiro-inositol concentration can be used to determine insulin-resistance, or a predisposition to the development of insulin-resistance, in type I and type II diabetics. Spot urine or serum samples reflecting concentrations of chiro-inositol below about 1.0 micrograms/ml in urine or 0.1 micrograms/ml in serum are indicative of a predisposition to the development of insulin-resistance, while concentrations below about 0.3 micrograms/ml or 0.03 micrograms/ml in serum are associated with actual insulin-resistance symptoms. The assay can be employed for patient diagnosis, insulin therapy monitoring, and family screening.

Abstract: A process is disclosed for the determination of the malignant potential of a tumor. The process comprises the steps of determining the amount of BBO in a tumor sample by reacting the BBO in a tumor sample with a BBO-binding lectin or a BBO-specific antibody to form a BBO-lectin or a BBO-specific antibody complex. Then, the amount of BBO-lectin or BBO-antibody complex or of unreacted BBO can be measured.

Abstract: The present invention is directed to a fluorescence polarization immunoassay for cyclosporin A and metabolites thereof. The present invention also relates to novel cyclosporin A derivative compounds useful in fluorescence polarization techniques. Included among the novel compounds are cyclosporin A derivatives where the amino acid in the first position is altered. The cyclosporin A derivatives are useful in forming immunogens for raising antibodies specific to cyclosporin A and metabolites thereof.

Abstract: Non-primate or primate cells are provided comprising a functional human transporter for neurotransmitter uptake. The cells allow for dissection of the mechanism of neurotransmitter transport, as well as screening for agonists and antagonists of the neurotransmitter with respect to its uptake. Methods are provided for producing such cells. Specifically, the cells are transformed with human DNA comprising the gene encoding for the neurotransmitter transporter, whereby this protein(s) is expressed and incorporated into the plasma membrane and is capable of functioning to transfer the neurotransmitter from the extracellular space to intracellular domains. The physiological, kinetic and pharmacological characteristics of transport in these cells conform to known characteristics of high-affinity neurotransmitter transport in the CNS.

Abstract: A novel bidentate conjugate has two different chemical moieties, or bidentate members, attached through an adequate spacer moiety. Each bidentate member acts as a small molecule ligand and is capable of specifically binding to a different macromolecular substance. The bidentate members are relatively small molecules, usually less than about 7,000 Daltons in size. The spacer moiety is selected so that both bidentate members can simultaneously bind to their respective specific binding partners. Where the specific binding partners are multivalent, large complexes can be formed. The formation of these complexes can be inhibited by the presence of an unconjugated monovalent bidentate member, such as free analyte from a test sample. The bidentate is of particular use in turbidimetric or nephelometric inhibition immunoassay procedures.

Abstract: An inventive bioassay method can be used to determine the presence in a fluid sample of a toxin having sodium channel-affecting activity. The method includes the steps of incubating a plurality of cultures of cells which are responsive in a dose-dependent manner to sodium channel-affecting toxins with (i) a medium comprising a solution of ouabain and veratridine and (ii) a portion of the fluid sample, each culture being incubated with a different concentration of the fluid sample; removing the medium and fluid sample from the cultures; incubating the cultures with a medium comprising an indicator which is acted upon by living cells to form a measurable product; measuring the amounts of product formed during the preceding step; and relating the amounts of product measured to a standard calibration curve to determine the presence of the toxin in the sample. The method is readily embodied in kit form and is amenable to automation.

Abstract: The invention relates to diagnosis of reactive conditions, such as malignant tumors. According to the invention, the amount of cellular fibronectin in a body fluid is determined, and an elevated amount is used as a marker for a reactive condition. The method is especially suitable for the diagnosis of carcinomas, such as colon carcinoma.

Abstract: There is provided a standard for use in testing for captan in immunoassays. This standard has the structure THPD--(CH.sub.2).sub.x --(R.sup.3).sub.y --R.sup.1 wherein THPD is cis-1,2,3,6-tetrahydrophthalimido, x is an integer from 1 to 10, R.sup.1 selected from the group consisting of --COOH, --NH.sub.2, --NO.sub.2, --SH and --OH, R.sup.3 is an aryl moiety and y is 0 or 1. Compounds of this general structure are known, they mimic the immunological reaction of captan and related compounds which are not stable in water and thus cannot be satisfactorily used as standards in testing for the presence and level of presence of captan and related compounds. There is also provided a method of carrying out such testing, utilizing such standards in which the standard (I) is coupled to a protein that is large enough to elicit an immune response in warm blooded animals, to yield compound (II). THPD--(CH.sub.2).sub.x --(R.sup.3).sub.y --R.sup.

Abstract: The present invention provides a process for the determination of low density lipoproteins (LDL) in body fluids, wherein high density lipoprotein (HDL) antibodies are added to a sample to be investigated, insolubles formed are separated off and the LDL or one of its components is determined in the supernatant.The present invention also provides a reagent for the determination of the LDL fraction in body fluids, wherein it contains HDL antibodies.

Abstract: A present invention relates to a method for quantitatively determining sugar-alcohols characterized by passing test samples containing sugar-alcohols, proteins, and saccharides through a column filled with basic anion-exchange resins which have a protein-removing ability and a saccharide-removing ability, and then quantitaing the sugar-alcohols in the effluent out of the column, a column filled with said resins and an aqueous solution of boric acid, and a kit. Sugar-alcohols such as 1,5-anhydroglucitol and the like have been calling attention as markers for diabetes mellitus recently.

Abstract: Immunoassay methods and reagents for the specific quantification of amitriptyline or nortriptyline in a test sample are disclosed employing antibodies prepared with amitriptyline or nortriptyline derivatives of the Formula III: ##STR1## wherein for amitriptyline, R is CH.sub.3, and for nortriptyline, R is H. The present invention also describes the synthesis of unique fluorescein tracers of the structure of Formula IV and Formula V: ##STR2## wherein for a specific amitriptyline immunoassay, W.sub.1 is a heteroatom linked to the aromatic ring at the 2 or 3 position, and for a specific nortriptyline immunoassay, W.sub.2 is two heteroatoms linked together and attached to the aromatic ring at the 2 or 3 position, and wherein Q is a detectable moiety, preferably fluorescein or a fluorescein derivative.

Abstract: The invention relates to a novel process for preparing immunoconjugates consisting of haptens which are sparingly soluble or insoluble in aqueous solution and proteins/polypeptides using special solvents, in particular diethylene glycol monoalkyl ethers.

Abstract: A method of assaying for acyl-L-carnitines including short chain acyl-carnitines including acetyl-L-carnitine and propionyl-L-carnitine in a substance, comprises subjecting a sample of the substance to be analyzed to an enzymatic hydrolysis using an acyl-carnitine esterase. The esterase is produced by Alcaligenes sp. FERM BP-2570 and it has substrate specificity for acyl-L-carnitines including short-chain acyl-L-carnitines. In addition the esterase demonstrates substrate specificity for acetyl-L-carnitine and propionyl-L-carnitine. The enzyme facilitates the hydrolysis reaction of one mole each of the acyl-L-carnitines with one mole of water in which to form one mole each of the corresponding fatty acid and L-carnitine. The amount of the fatty acid and L-carnitine formed is determined by this method.

Abstract: Methods and reagents for determining the lapse of time since an acute disease event, such as the occurrence of a myocardial infarction, are presented. A serum or plasma sample is assayed to determine the concentration of two different analytes selected from the group consisting of creatine kinase-MB species and creatine kinase-BB species. From these measurements, the time of the acute event can be more accurately determined. Novel antibodies, labeled and insolubilized derivatives of these antibodies, labeled proteins, and kits containing one or more of these reagents are also described.

Abstract: Methods and reagents for determining the lapse of time since an acute disease event, such as the occurrence of a myocardial infarction, are presented. A serum or plasma sample is assayed to determine the concentration of two different analytes selected from a group of creatine kinase-MB species. From these measurements, the time of the acute event can be more accurately determined. Novel antibodies, labeled and insolubilized derivatives of these antibodies, labeled proteins, and kits containing one or more of these reagents are also described.

Abstract: A method for determining chondrocalcin through an immunoassay using an enzyme(s)-labeled mammalian chondrocalcin or enzyme(s)-labeled anti-chondrocalcin antibody which is characterized by that mammalian body fluid is used as a specimen and immunoreaction in a solution is utilized to determine the chondrocalcin of the mammalian, reagents and a kit therefor.This determination can be utilized for diagnosis or the like for cartilage-relating diseases in mammals.

Abstract: A method of detecting the presence and amount of a nitrate ester of a polyol in an unknown comprises preparing an antigen based on such an ester and using that antigen to raise antibodies for use in a biochemical assay for the nitrate ester. A preferred antigen is pentaerythritol trinitrate bonded to a protein such as thyroglobulin or BSA. Antibodies can be raised against this antigen in rabbits or other normally used laboratory animals, and the antibodies are used in, for example, a competitive inhibition enzyme immunosorbent assay (CIEIA).

Abstract: The invention relates to a method of detecting gram-negative bacterial endotoxin using antibody capture combined with amoebocyte lysate chromogenic detection. The method is highly sensitive and rapid and may be used for detection of specific endotoxin. In a particular application, picogram levels of Haemophilus influenzae type b endotoxin are detected in plasma taken from previously infected mammals. In another particular application, the method is applied to the detection and diagnosis of disease, through the detection of endotoxin from disease-causing organisms. A specific example is the diagnosis of chancroid through the detection of endotoxin from H. ducreyi.

Abstract: Disclosed is a substantially optically pure hapten, useful in an immunoassay for dextropropoxyphene and/or nordextropropoxyphene. The hapten corresponds to a specified structural formula (IX).Also disclosed is an immunogen derived from the hapten as well as an antibody raised in response to an immunogen derived from the hapten.Also disclosed is a fluorescent tracer derived from a substantially optically pure compound corresponding to the hapten, the tracer being useful in an immunoassay for dextropropoxyphene and/or nordextropropoxyphene.Also disclosed is an improved immunoassay for determining dextropropoxyphene and/or nordextropropoxyphene in a biological sample involving a step of contacting the sample with antibodies raised in response to the immunogen.

Abstract: A method for quantifying glucose concentration in blood, body fluids, and other samples within, below and above the normal physiological range, which relies on non-radiative fluorescence resonance energy transfer, as well as devices useful in quantifying blood glucose concentration using the present method.

Abstract: Immunoassay methods and reagents for the specific quantification of imipramine or desipramine in a test sample are disclosed. The measurement of imipramine or desipramine is accomplished in a specific immunoassay employing antibodies prepared with imipramine or desipramine derivatives of the Formula III: ##STR1## wherein P is an immunogenic carrier material, X is two heteroatoms, Y is a linking group comprising from 1 to 6 carbon atoms and P is an immunogenic carrier material, and wherein for imipramine, R is CH.sub.3, and for desipramine, R is H.The present invention also describes the synthesis of unique labeled reagents of the structure of the Formula IV: ##STR2## wherein Z is a linking group comprising 1 to 4 carbon atoms and 0 to 2 heteroatoms and Q is a detectable moiety, preferably fluorescein or a fluorescein derivative, and wherein for imipramine, R.sub.1 is CH.sub.3, and for desipramine, R.sub.1 is H.

Abstract: The precision of identification of analyte composition in a sample, where the possible analytes cross-react with specific binding reagents, is enhanced by applying pattern recognition techniques. Samples to be tested are reacted with a panel of specific binding reagents reactive with the set of analytes to be tested to obtain a pattern of reactivity with respect to each analyte at a given concentration. This results in a databank of "CRIM profiles" for known concentrations of each analyte. This databank is stored in a computationally accessible form, which then can be matched against CRIM patterns obtained by testing unknown samples. In one embodiment, each CRIM pattern obtained is plotted as a single point in n-dimensional space, wherein n represents the number of specific binding reagents in the panel.

Abstract: A fluorescence polarization immunoassay for flecainide and tracers therefor are disclosed.

Abstract: Methods are described for making specific monoclonal antibodies useful for detection of cyclodienes in foods and environmental samples. Monoclonal antibodies specifically reactive with cyclodienes can detect accumulated pesticides in food, tissue or environmental samples. Extraction and preparation of organic samples for immunoassay in a polar-nonpolar reaction medium permits detection of halogenated organic ring structures at concentrations in samples.

Abstract: Immunoassay methods and reagents for the quantification of total doxepins (i.e., E-doxepin, Z-doxepin, E-desmethyldoxepin, and Z-desmethyldoxepin) in a test sample are disclosed. The quantification of total doxepins is accomplished in an immunoassay employing antibodies and labeled reagents prepared with doxepin derivatives of the Formula II: ##STR1## wherein Y--Z can be C.dbd.CH or N--CH.sub.2, R.sub.` is a linking group, R.sub.2 can be H or CH.sub.3, and Q can be a detectable moiety or an immunogenic carrier material. The antibody reagent comprises antibodies which are capable of binding to total doxepins and which are produced with one or more immunogens prepared from the doxepin derivative of Formula II, and the labeled reagent is also prepared from the doxepin derivative of Formula II.